Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature
G Lombardi, F Zustovich, P Farina, P Fiduccia… - Anti-cancer …, 2013 - journals.lww.com
Abstract Treatment with angiogenesis inhibitors is becoming a cornerstone of modern
anticancer therapy. Hypertension (HTN) is a common adverse event during antiangiogenic
treatment and might represent a cancer biomarker in patients with recurrent glioblastoma
treated with angiogenesis inhibitors. In a retrospective study, we analyzed 53 patients with
recurrent glioblastoma treated with antiangiogenic drugs. Thirty patients were treated with
sorafenib and 23 patients were treated with bevacizumab. All patients underwent brain …
anticancer therapy. Hypertension (HTN) is a common adverse event during antiangiogenic
treatment and might represent a cancer biomarker in patients with recurrent glioblastoma
treated with angiogenesis inhibitors. In a retrospective study, we analyzed 53 patients with
recurrent glioblastoma treated with antiangiogenic drugs. Thirty patients were treated with
sorafenib and 23 patients were treated with bevacizumab. All patients underwent brain …
以上显示的是最相近的搜索结果。 查看全部搜索结果